Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-1 of 1

Sort by

Sort Order Select

Journal Articles

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations

Matilde Slot, Carsten Utoft Niemann, Lars Holger Ehlers, Emelie Curovic Rotbain

Blood Adv (2023) 7 (15): 4186–4196.

https://doi.org/10.1182/bloodadvances.2023010108

Published: 2023

Includes: Supplemental data